Asset profile
Lorundrostat
Small molecule
Evidence outlook · registrational
Hypertension: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT05769608: The study randomized 285 participants to lorundrostat or placebo and maintained double blinding, using change in ambulatory systolic blood pressure as a clinical primary endpoint. Because the primary comparison and statistical result have not been reported, the evidence supports a moderate preliminary grade rather than a strong one.
Also in development:Chronic Kidney Disease · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.